Oncotarget

Research Papers:

The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer

Lan-Ying Gou _, An-Na Li, Jin-Ji Yang, Xu-Chao Zhang, Jian Su, Hong-Hong Yan, Zhi Xie, Na-Na Lou, Si-Yang Liu, Zhong-Yi Dong, Hong-Fei Gao, Qing Zhou, Wen-Zhao Zhong, Chong-Rui Xu and Yi-Long Wu

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:51311-51319. https://doi.org/10.18632/oncotarget.9697

Metrics: PDF 3646 views  |   HTML 2786 views  |   ?  


Abstract

Lan-Ying Gou1,2,*, An-Na Li2,*, Jin-Ji Yang2,*, Xu-Chao Zhang2, Jian Su2, Hong-Hong Yan2, Zhi Xie2, Na-Na Lou2, Si-Yang Liu2, Zhong-Yi Dong2, Hong-Fei Gao2, Qing Zhou2, Wen-Zhao Zhong2, Chong-Rui Xu2, Yi-Long Wu2

1Southern Medical University, Guangzhou, Guangdong, People’s Republic of China

2Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China

*These authors have contributed equally to this work

Correspondence to:

Yi-Long Wu email: [email protected]

Keywords: non-small cell lung cancer, EGFR-TKI, acquired resistance, MET, T790M

Received: March 19, 2016     Accepted: May 13, 2016     Published: May 30, 2016

ABSTRACT

MET overexpression and the EGFR T790M mutation are both associated with acquired resistance (AR) to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in advanced non-small cell lung cancer (NSCLC). We characterized the frequency, underlying molecular mechanisms, and subsequent treatment for AR in MET overexpressing NSCLC patients with or without the T790M mutation. The study participants were 207 patients with advanced NSCLC and AR to EGFR-TKIs. The percentages of MET-, T790M- and MET/T790M-positive patients were 20.3% (42/207), 34.8% (72/207) and 6.8% (14/207), respectively. The disease control rate was 100% (5/5) for five patients with MET overexpression who received EGFR-TKIs plus a MET inhibitor. Among the MET/T790M-positive patients, seven received EGFR-TKIs plus a MET inhibitor and four received a T790M inhibitor, but no response was observed. The median post-progression survival (PPS) was 14.1, 24.5, and 10.7 months for MET-overexpressing, T790M-positive and MET/T790M-positive patients, respectively (P=0.044). c-Met, p-Met, ERBB3, and p-ERBB3 were highly expressed in MET-positive and MET/T790M-positive patients, but were poorly expressed in T790M-positive patients. EGFR, p-EGFR, AKT, p-AKT, MAPK, and p-MAPK were highly expressed in all three groups. These results suggest that MET/T790M-positive patients are at higher risk of AR to EGFR-TKIs, and have a worse PPS than patients with only MET overexpression or the T790M mutation alone. Clinical trials are needed to determine the best treatment for patients with both MET overexpression and the EGFR T790M mutation.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9697